Evotec AG O.N. (EVTd)

17.18
+0.50(+2.95%)
  • Volume:
    146,401
  • Bid/Ask:
    0.00/0.00
  • Day's Range:
    17.08 - 17.50

EVTd Overview

Prev. Close
16.88
Day's Range
17.08-17.5
Revenue
670.41M
Open
17.34
52 wk Range
15.79-44.94
EPS
-1.02
Volume
146,401
Market Cap
3.02B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
107,607
P/E Ratio
-18.43
Beta
1.15
1-Year Change
-59.27%
Shares Outstanding
176,702,738
Next Earnings Date
Mar 30, 2023
What is your sentiment on Evotec AG?
or
Market is currently closed. Voting is open during market hours.

Evotec AG O.N. News

Evotec AG O.N. Analysis

Evotec AG O.N. Company Profile

Evotec AG O.N. Company Profile

Employees
4521
Market
Germany
  • Type:Equity
  • Market:Germany
  • ISIN:DE0005664809

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications of diabetes, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women’s health. It has collaboration agreements with Bayer AG; Lilly; Chinook Therapeutics; Novo Nordisk A/S; Galapagos; Pfizer Inc.; CONBA Pharmaceutical Co., Ltd.; Bristol Myers Squibb Company; Zhejiang JingXin Pharmaceutical Co., Ltd; Kazia Therapeutics; Apeiron Biologics; and Takeda Pharmaceuticals. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.

Read More

Analyst Price Target

Average29.79 (+74.42% Upside)
High50
Low21
Price17.08
No. of Analysts12
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Analysts 12-Month Price Target

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesSellSellSellSellStrong Sell
Technical IndicatorsSellStrong BuyBuySellStrong Sell
SummarySellNeutralNeutralSellStrong Sell
  • To be fair the stock has had large (lazy) short positions for many months and the US DoD deal is not new news. Also, the sceince of  monoclonal antibodies is still not proven. That said, as a pipeline of royalties begin to come through adding to top lines my outlook remains  €50 target in 3 years.
    0
    • lol railing Melvin Capital left and right
      0
      • Doesnt have anything to do with that here but rather the us military filing in a huge order at evotec for anti bodies against covid (over the next 7 years)
        0
    • The valuation is very much a "sum of the parts" not a not a future valuation. The potentials from a series of bolt on company purchases and ongoing strategic alliances will see a valuation of €10Bn within the next 5 years. What is not priced in to the current valuation is the vision of the management  and shear quality of the science.. . Volatility is an issue so hold on to your hat !!. . Still not convinced ? Where else could you have got 50%+ return on stocks for the past three years ??
      0